Hims & Hers tumbles 27% as investors fear uncertainty without compounded weight-loss drugs

Key Points

  • Hims & Hers (HIMS) stock dropped 27% after hinting at stopping some compounded weight-loss drugs.
  • Despite strong Q4 results, investors worried about revenue loss from GLP-1 segment.
  • CFO Yemi Okupe emphasized that weight-loss business is only a part of their revenue, with other segments contributing significantly.
  • The company reported $1.5 billion in revenue for 2024, with $1.2 billion from non-GLP-1 sources.
  • Hims & Hers forecasted higher full-year revenue than Wall Street estimates, yet the market reaction was cautious.

Summary

Hims & Hers Health, Inc. experienced a significant stock drop of 27% after suggesting it might discontinue some compounded versions of weight-loss drugs due to regulatory concerns. Despite reporting better-than-expected fourth-quarter results, the potential revenue loss from the GLP-1 segment, which includes drugs for diabetes and weight loss, caused investor unease. CFO Yemi Okupe reassured that while the weight-loss segment is growing, it constitutes only a fraction of their business, with other services contributing the majority of their $1.5 billion revenue in 2024. The company plans to comply with regulatory requirements, potentially removing semaglutide from their offerings. Despite these assurances, the market remained cautious, with Hims & Hers forecasting a higher revenue for the year than Wall Street's estimates. The stock's decline comes after a surge in 2022 due to the popularity of compounded semaglutide, but recent FDA actions regarding drug shortages have impacted the stock's performance.

yahoo
February 25, 2025
Stocks
Read article

Related news